Bambusa Therapeutics Raises $90M in Series A
Boston-based Bambusa Therapeutics has raised $90 million in a Series A funding round to fuel the development of bispecific antibodies targeting immunological and inflammatory (I&I) disorders. The early-stage biotech company,…